Uses of Insunova 30/70

Insunova 30/70 drug is very commonly used in the treatment of type I, type II diabetes and gestational diabetes. So what is the dose of Insunova 30/70 and what precautions should be taken when using it?

Insunova 30/70 100IU/ml is a medicinal product of Biocon Limited. The main ingredient of Insunova 30/70 is Insulin human packaged in a 10ml vial. The hypoglycemic effect of insulin is due to glucose uptake after insulin binds to receptors on muscle and fat cells, and inhibits glucose production in the liver. The half-life of insulin in the blood lasts for about a few minutes, so the duration of action of an insulin preparation such as Insunova 30/70 is determined only by absorption properties. This process is influenced by a number of factors such as: insulin dose, sugar and injection site, so this is why it is important to consider variability from patient to patient and from patient to patient.
Insulin after entering the body will be metabolized in the liver and kidneys, a small amount is metabolized in muscle and adipose tissue. Insulin binds to receptors on the cell surface, is then taken into the cells and degraded by the enzyme Insulin glutathione transhydrogenase into A and B chains. When Insunova 30/70 is injected subcutaneously, the action starts. Initial exposure occurs within 30 minutes after injection, peak concentrations are reached in 2-8 hours, duration of action may be up to 24 hours.
The average course of action after subcutaneous injection of Insunova 30/70 is as follows:
Start of action in 30 minutes; Maximum impact: 2 - 8 hours; Duration of action: 24 hours.

Insunova 30/70 is indicated for use in the treatment of diabetes:
Diabetes requires insulin to maintain stable blood sugar; Initial control of diabetes, diabetes in pregnancy.

How to use Insunova 30/70: subcutaneous injection. Usually, Insunova 30/70 mixture is injected 1 or 2 times per day, subcutaneously, preferably before meals to give the drug a rapid onset of action and a longer lasting effect.
The ideal time to take Insunova 30/70, but not always, is within 30 minutes after a main meal or carbohydrate snack. The injection site of Insunova 30/70 should be rotated in one area of ​​the body to avoid lipodystrophy. In patients with diabetes, optimal glycemic control slows the course of diabetic complications, so close monitoring of blood glucose is recommended. Do not use Insunova 30/70 for intravenous injection.
Instructions on how to inject Insunova 30/70 : Inject insulin under the skin, using the injection technique described in the instructions for use. Hold the needle under the skin for at least 10 seconds to ensure that an adequate dose of Insunova 30/70 is released. After each injection of Insunova 30/70, the needle should be removed.
Dosage of Insunova 30/70 is individualized and determined by the doctor according to the needs of each patient. The average daily insulin dose for the treatment of diabetes mellitus ranges from 0.3 to 1.0 IU/kg depending on the individual patient's metabolic status and glycemic control.
Note: The above dose of Insunova 30/70 is for reference only, the specific dose depends on the condition and progression of the disease, it is necessary to consult a doctor or medical professional to get the most accurate dose.

No specific case of overdose with Insunova 30/70 has been identified, however hypoglycemia can develop sequentially in the following stages:
Mild hypoglycemia phase, this is the phase can be treated by taking glucose or by taking sugary products. Therefore, doctors often recommend that diabetics always carry some sugar cubes, sweets, cookies or sugary fruit juice with them whenever they go out. Severe hypoglycaemic phase: hypoglycaemic patients may become unconscious and should be treated with glucagon (0.5-1 mg) intramuscularly, subcutaneously, or intravenously under the supervision of a medical professional. economic. If necessary, intravenous glucose should be given if the patient does not respond to glucagon within 10 to 15 minutes. After regaining consciousness, the patient is advised to eat carbohydrate-containing foods to prevent recurrence of dangerous hypoglycemia.

Compliance with the time of using Insunova 30/70 is extremely important. In case of forgetting to take Insunova 30/70, it is best to measure blood glucose and add 1 dose of Insulin (regular) if the glucose level is too high. If not, wait until the next dose of Insunova 30/70 after the course of treatment.

When using Insunova 30/70, patients may experience serious undesirable effects (ADRs): hypoglycemia is the most frequent undesirable effect that occurs if the insulin dose is too high for the needs. . Symptoms of hypoglycemia may be caused by the release of adrenaline or by an inadequate supply of glucose to the brain. Mild hypoglycemia can cause restless sleep, nightmares, and cold sweats that wake the patient at night. Severe hypoglycemia, a lack of glucose to the brain causes slurred speech, impaired concentration, confusion, convulsions, coma, irreversible brain damage, and even death.
Common Insunova 30/70 side effects: Mild to moderate hypoglycemia causing cold sweats, anxiety, tremors, hunger, tachycardia, headache, nervousness.
Uncommon side effects of Insunova 30/70: Anaphylactic reactions and lipid dystrophy may occur at the injection site of Insunova 30/70, a consequence of the failure to rotate the injection site. Edema may also occur at the initiation of insulin therapy, but these symptoms are usually temporary in nature.

Insunova 30/70 is contraindicated in the following cases:
Hypoglycemia; Hypersensitivity to insulin human or any component of Insunova 30/70.

Inadequate dosing or discontinuation of Insunova 30/70 treatment, especially in type 1 diabetes, can lead to hyperglycemia and diabetic ketoacidosis. The first symptoms of hyperglycemia that appear over several hours or days include increased thirst, increased frequency of urination, nausea, vomiting, lethargy, red, dry skin, dry mouth, and loss of appetite. , there is an odor of acetone on the breath. Do not use Insunova 30/70 beyond the expiry date printed on the package. Insunova 30/70 is a water-based, milky suspension containing human insulin, so it is forbidden to use Insunova 30/70 which is not uniform translucent white after gentle rotation. Insunova 30/70 contains m-cresol which may lead to type M allergic reactions (delayed hypersensitivity reactions). Do not stop injecting Insunova 30/70 on your own, unless ordered by your doctor. Switching from Insunova 30/70 to another type of insulin or a different brand name should be done under close supervision. Changes in content, brand, type (fast-acting, intermediate-acting, long-acting...), type (insulin of animal origin) may need to change the dose. Patients switching to Insunova 30/70 or from Insunova 30/70 may need a change in their usual insulin dose for the first few days or weeks. In patients where blood glucose control has significantly improved, there may be a change in the usual warning symptoms of hypoglycaemia and appropriate counseling should be sought. An increase in hypoglycaemic reactions has been reported in some patients when switching from insulin of animal origin, the early warning symptoms of hypoglycaemia are less pronounced and different from those on insulin. before. Dose adjustment is necessary if the patient increases physical activity or changes the usual diet, the patient suddenly develops bacterial infections and symptoms similar to fever, these factors often increase insulin requirements. Alcohol is a substance that can enhance and prolong the hypoglycemic effect of insulin. The patient's ability to concentrate and react quickly may be impaired as a result of hypoglycemia, so precautions should be taken to prevent hypoglycemia while driving, which is especially important for people with cognitive impairment. Be aware of the warning signs of low blood sugar. Pregnancy: There are no restrictions on the use of Insunova 30/70 for the treatment of gestational diabetes because insulin does not cross the placental barrier. When treating diabetes in pregnant women, it is advisable to strengthen glycemic control throughout pregnancy and even when just contemplating pregnancy. Pregnant women's insulin requirements usually decrease during the first trimester of pregnancy and then increase during the second and third trimesters. After delivery, the mother's insulin needs will quickly return to pre-pregnancy levels. There is no restriction on the use of insulin for the treatment of diabetes in lactating women as there is no risk to the baby, however insulin requirements usually tend to decrease during lactation, monitor blood glucose at home to avoid the risk of hypoglycemia and the need to reduce the dose of insulin.

Some drugs have the potential to interact with insulin because of their involvement in glucose metabolism. Therefore, physicians should be aware of the potential for possible interactions:
Certain drugs that decrease insulin requirements: Oral hypoglycemic agents, Octheotride, monoamine oxidase inhibitors, beta blockers Non-selective, angiotensin-converting enzyme inhibitors, salicylate, alcohol, anabolic steroids. Some drugs increase insulin requirements: Oral contraceptives, Thiazide diuretics, Glucocorticosteroids, thyroid hormones, sympathomimetic drugs, Danazol,... Beta-blockers can cause side effects such as: mask the symptoms of hypoglycemia. Store Insunova 30/70 in the refrigerator at a temperature of 2 - 8°C, do not let the medicine freeze. The suspension can be stored at room temperature (below 25°C) for up to 6 weeks once the vial has been used, but should not be exposed to heat and direct sunlight.